Meagan Hamblin

Meagan Hamblin serves as a Consultant in the Medical Affairs Advisory Group at Syneos Health. She began her role in June 2024 after approximately three years at Eversana Consulting. Prior to entering the pharmaceutical industry, Hamblin worked as a research associate for two years at the Broad Institute of MIT and Harvard, where she conducted bench science focused on molecular mechanisms of infectious diseases. She then pursued and completed a PhD at Stanford School of Medicine over seven years of graduate study. In her current consulting position, Hamblin assists pharmaceutical and biotech clients with commercialization strategies, prepares literature summaries and analyses, supports advisory board meetings with leading experts, and contributes to launch and brand planning. Her remote role allows her to engage with a diverse range of clients, from large pharmaceutical organizations to small emerging biotechs. Hamblin transitioned from academia to industry to help communicate scientific breakthroughs more effectively to physicians and patients, addressing gaps in awareness of new treatments and clinical options.